Changshan Pharmaceutical: La solución inyectable de heparina sódica enoxaparina obtiene el certificado de registro de medicamentos en Tayikistán

Changshan Pharmaceutical announces that the company’s drug, Enoxaparin Sodium Injection, has recently received a drug registration certificate issued by the Tajikistan drug regulatory authority. This medication is used to prevent venous thromboembolism, treat deep vein thrombosis, and in combination with aspirin for the treatment of unstable angina. The approval of this registration document will have a positive impact on the company’s expansion into overseas markets.